Mumbai: British drug multinational GSK Plc’s unit GSK Pharmaceuticals Ltd posted 9% growth in net profit at Rest 147.54 core during the second quarter ended 30 June. During the year ago quarter, it’s net profit was Rs 128.9 core. While, the net sales grew by 13% to Rs 561.54 core from Rs 497.93 core of the quarter a year ago.
“The company’s growth has been in line with the industry growth. In particular, oncology, dermatologicals and mass specialty therapies have grown well. In addition to the base effect, vaccines have shown strong market competitive growth,” said managing director Hasit Joshipura.
GSK had launched a branded generic and another product in dermatology during the quarter apart from two original products from the parent’s pipeline in oncology and haematology.
Sales of the core pharmaceuticals and vaccines business grew by 14%, and the operating profit margin was maintained at 35% in line with the first quarter of 2011, said a statement from the company.